Is the stock adaptimmune eligible for short squeeze

Adaptimmune Therapeutics (ADAP) is not currently eligible for a short squeeze based on the following analysis:

1. Short Interest Ratio: Adaptimmune's short interest ratio is 3.50 days to cover. This indicates that it would take approximately 3.50 days for short sellers to close their positions if they were to buy back shares at the current rate of trading. While a short interest ratio this high suggests strong bearish sentiment, it does not reach the threshold where a short squeeze is typically considered imminent.
2. Short Volume: The off-exchange short volume ratio for Adaptimmune is 28.02%. This indicates that a significant portion of the short interest is being covered through dark pool trades, which can make it more difficult to trigger a short squeeze.
3. Market Sentiment: The pending launch of Adaptimmune's afami-cel, assuming FDA approval, marks a transition to commercialization. This could potentially increase volatility and attract more investors, which might include short sellers looking to capitalize on potential price declines. However, without a significant increase in price, a short squeeze is not likely to occur.
4. Financial Performance: Adaptimmune's financial reports show a net loss of $150.276 million and a negative P/E ratio. This financial performance could mitigate the risk of a short squeeze, as it indicates the company is currently unprofitable and may not be perceived as a strong investment.

In conclusion, while Adaptimmune has a high short interest ratio, the current market conditions and financial performance do not strongly suggest an imminent short squeeze. However, if there were a significant positive development, such as FDA approval of afami-cel and a subsequent surge in price, that could potentially change the outlook and create conditions for a short squeeze.